Yokohama City University Medical Center, Center of IBD
Welcome,         Profile    Billing    Logout  
 8 Trials 
28 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Otley, Anthony
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
PAZAZ, NCT04186247: Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

Completed
2
12
Europe, Canada, US, RoW
Azithromycin, Zithromax, Zmax, Metronidazole, Flagyl, Standard of Care
University of North Carolina, Chapel Hill, Crohn's and Colitis Foundation, University of Amsterdam
Crohn Disease, Pediatric Crohns Disease
12/23
12/23
NCT03630146: iPeer2Peer Program for Adolescents With Inflammatory Bowel Disease

Completed
N/A
150
Canada
iPeer2Peer program, Waitlist control
The Hospital for Sick Children
Inflammatory Bowel Diseases
03/22
03/22
mRE-EEN, NCT06216899: Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial

Recruiting
N/A
60
Canada, US
Whole-food based smoothie, Formula
Seattle Children's Hospital, Children's Hospital of Philadelphia, Dalhousie University
Crohn Disease
04/26
01/27
CIDsCaNN, NCT02308917: The Canadian Children Inflammatory Bowel Disease Network

Recruiting
N/A
2400
Canada
The Hospital for Sick Children, Children's Hospital of Eastern Ontario, British Columbia Children's Hospital, Alberta Children's Hospital, Stollery Children's Hospital, IWK Health Centre, Montreal Children's Hospital of the MUHC, St. Justine's Hospital, Health Sciences Centre, Winnipeg, Manitoba, Eastern Health, Children's Hospital of Western Ontario, McMaster Children's Hospital
Inflammatory Bowel Diseases, Crohn's, Ulcerative Colitis
04/26
04/26
Yerushalmi, Baruch
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease (CD)
11/24
11/24
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
Aloi, Marina
Vedolizumab-3041, NCT06443502: A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

Recruiting
3
30
Europe, RoW
Vedolizumab, Entyvio, MLN0002, Kynteles, Concomitant Antibiotic Therapy
Takeda
Pouchitis
12/29
12/29
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease (CD)
11/24
11/24
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting
3
240
Europe, Canada, Japan, US, RoW
Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention
Takeda, Takeda Development Center Americas, Inc.
Ulcerative Colitis, Crohn's Disease
08/31
08/31
APTITUDE, NCT04492683 / 2019-004523-21: Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children

Recruiting
2
230
Europe, Canada, US
DBV1605
DBV Technologies
Cow's Milk Allergy
03/24
03/24
Kunisaki, Reiko
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
Gehring, Stephan
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Recruiting
3
60
Europe, Canada, Japan, US, RoW
Mirikizumab IV, LY3074828, Mirikizumab SC
Eli Lilly and Company
Ulcerative Colitis
07/26
03/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30
VIALA, Jérôme
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
RAPA-4-PAF, NCT06308445: Safety Study for the Use of Rapamycin in Children with Familial Adenomatous Polyposis

Not yet recruiting
2
25
Europe
Rapamycin
University Hospital, Toulouse
Familial Adenomatous Polyposis
08/30
08/30
T-FORE, NCT05202990: Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis

Not yet recruiting
2
26
Europe
Fecal Microbiota Transplantation by Stool capsules, UC treatment, Fecal Microbiota Transplantation by Intra-rectal enemas, UC Treatment
Assistance Publique - Hôpitaux de Paris, MRSU 938 - Research Center of Saint Antoine
Pediatric Ulcerative Colitis in Remission
09/26
09/28
MICE, NCT05652166: What Information is Remembered by Parents Following the Ingestion of Foreign Body by Their Child?

Recruiting
N/A
40
Europe
telephone interview
Assistance Publique - Hôpitaux de Paris
Information Remembered by Parents Following the Ingestion of Foreign Body by Their Child
05/23
05/23
Bracci, Fiammetta
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease

Recruiting
3
150
Europe, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
07/30
07/30

Download Options